BeyondSpring (NASDAQ:BYSI) Stock Price Passes Below Fifty Day Moving Average – Time to Sell?

BeyondSpring Inc. (NASDAQ:BYSI)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.60 and traded as low as $1.46. BeyondSpring shares last traded at $1.49, with a volume of 9,890 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

BeyondSpring Trading Down 2.0%

The firm’s 50 day moving average is $1.60 and its two-hundred day moving average is $1.72. The firm has a market cap of $61.27 million, a P/E ratio of -9.93 and a beta of 0.42.

BeyondSpring (NASDAQ:BYSI) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.49.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 40.29% of the company’s stock.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.